Allianz Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-9,700
| Closed | -$408K | – | 2333 |
|
|
2024
Q4 | $408K | Sell |
9,700
-14,300
| -60% | -$709K | ﹤0.01% | 1922 |
|
|
2024
Q3 | $1.33M | Buy |
24,000
+13,600
| +131% | +$693K | ﹤0.01% | 1545 |
|
|
2024
Q2 | $427K | Sell |
10,400
-2,800
| -21% | -$120K | ﹤0.01% | 1884 |
|
|
2024
Q1 | $616K | Sell |
13,200
-7,000
| -35% | -$330K | ﹤0.01% | 1552 |
|
|
2023
Q4 | $966K | Buy |
20,200
+11,700
| +138% | +$454K | ﹤0.01% | 1612 |
|
|
2023
Q3 | $303K | Hold |
8,500
| – | – | ﹤0.01% | 2061 |
|
|
2023
Q2 | $392K | Buy |
+8,500
| New | +$394K | ﹤0.01% | 1799 |
|
|
2022
Q3 | – | Sell |
-25,495
| Closed | -$1.52M | – | 2079 |
|
|
2022
Q2 | $1.52M | Sell |
25,495
-10,365
| -29% | -$638K | ﹤0.01% | 1521 |
|
|
2022
Q1 | $2.6M | Buy |
35,860
+2,672
| +8% | +$186K | ﹤0.01% | 1499 |
|
|
2021
Q4 | $2.79M | Sell |
33,188
-10,173
| -23% | -$828K | ﹤0.01% | 1477 |
|
|
2021
Q3 | $3.91M | Buy |
43,361
+24,799
| +134% | +$2.24M | ﹤0.01% | 1375 |
|
|
2021
Q2 | $1.77M | Buy |
18,562
+418
| +2% | +$43.5K | ﹤0.01% | 1512 |
|
|
2021
Q1 | $2.07M | Sell |
18,144
-462
| -2% | -$62.9K | ﹤0.01% | 1393 |
|
|
2020
Q4 | $2.58M | Buy |
18,606
+4,740
| +34% | +$562K | ﹤0.01% | 1246 |
|
|
2020
Q3 | $1.14M | Buy |
13,866
+938
| +7% | +$77.8K | ﹤0.01% | 1394 |
|
|
2020
Q2 | $1.01M | Buy |
+12,928
| New | +$856K | ﹤0.01% | 1825 |
|
|
2019
Q2 | – | Sell |
-31,364
| Closed | -$2.17M | – | 2749 |
|
|
2019
Q1 | $2.17M | Buy |
31,364
+12,431
| +66% | +$710K | ﹤0.01% | 1815 |
|
|
2018
Q4 | $823K | Buy |
+18,933
| New | +$1.03M | ﹤0.01% | 2101 |
|
|
2017
Q3 | – | Sell |
-5,701
| Closed | -$354K | – | 2661 |
|
|
2017
Q2 | $354K | Sell |
5,701
-857
| -13% | -$51.6K | ﹤0.01% | 2482 |
|
|
2017
Q1 | $445K | Sell |
6,558
-2,001
| -23% | -$152K | ﹤0.01% | 2419 |
|
|
2016
Q4 | $602K | Sell |
8,559
-11,029
| -56% | -$782K | ﹤0.01% | 2340 |
|
|
2016
Q3 | $1.39M | Buy |
+19,588
| New | +$1.25M | ﹤0.01% | 2117 |
|
|
2016
Q2 | – | Sell |
-103,933
| Closed | -$6.58M | – | 2599 |
|
|
2016
Q1 | $6.58M | Sell |
103,933
-44,257
| -30% | -$2.9M | 0.01% | 1332 |
|
|
2015
Q4 | $16.7M | Sell |
148,190
-29,724
| -17% | -$2.97M | 0.02% | 831 |
|
|
2015
Q3 | $17.1M | Buy |
177,914
+57,289
| +47% | +$6.56M | 0.02% | 770 |
|
|
2015
Q2 | $12.4M | Buy |
120,625
+86,625
| +255% | +$6.73M | 0.01% | 1005 |
|
|
2015
Q1 | $2.11M | Buy |
+34,000
| New | +$1.89M | ﹤0.01% | 1511 |
|
Other funds holding RARE
SCM
Allianz Asset Management's RARE Position: Q1 2025 in Review
Allianz Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 9,700 shares — an estimated $408K sold.
Allianz Asset Management first reported a position in RARE in Q1 2015 and held it in 27 quarters. The position peaked at $17.1M in Q3 2015. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.
- Allianz Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
- Allianz Asset Management sold 9,700 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $408K.
- Allianz Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 27 quarters.
- Allianz Asset Management's Ultragenyx Pharmaceutical position peaked at $17.1M in Q3 2015.
- 299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.
Based on Allianz Asset Management's 13F filing for Q1 2025, filed 5 May 2025.